Radiopharm (ASX:RAD) ropes in Dr Shmeis as senior VP of Chemistry, Manufacturing, and Controls - Kalkine Media

Highlights

• Radiopharm has appointed Dr Rama Abu Shmeis as Senior Vice President (SVP), Chemistry, Manufacturing, and Controls (CMC).
• Dr Shmeis has more than two decades of experience in the various aspects of CMC development and production across all stages.
• Dr Shmeis holds a PhD in Pharmaceutics and a Bachelor of Science in Pharmacy.

ASX-listed radiopharmaceuticals firm Radiopharm Theranostics (ASX:RAD) has strengthened its team with the addition of highly experienced executive Dr Rama Abu Shmeis as Senior Vice President (SVP), Chemistry, Manufacturing, and Controls (CMC).

Dr Shmeis has more than two decades of experience in leading strategic, operational, and scientific aspects of CMC development and production, from the pre-clinical stage to commercialisation. She has experience with studies across various dose forms, products, and technologies.

Dr Shmeis – A highly accomplished executive

She has led the advancement of more than 25 new molecular entities on a speed-to-market timeline focusing on science, innovation, and quality. Moreover, she has headed successful global regulatory CMC submissions, approvals and market launches across several areas including oncology, virology, neuroscience, and pain management.

She has also been engaged in CMC due diligence evaluations leading to several acquisitions, in-licensing, outlicensing and strategic alliances.

Dr Shmeis holds an excellent record in developing and leading highly functional teams of scientists and engineers, working toward aggressive timelines, and managing external partners and Contract Development and Manufacturing Organizations (CDMOs). 

Professional tenure - Prior to joining Radiopharm, Dr Shmeis served as Vice President CMC & Manufacturing Operations at each of B-cell disease-focused TG Therapeutics and immunotherapy developer Checkpoint Therapeutics. She served at these NASDAQ-listed companies for more than five years.

Moreover, she has worked with Keryx Biopharmaceuticals, Eagle Pharmaceuticals, Purdue Pharma, Boehringer-Ingelheim Pharmaceuticals, Sanofi-Aventis, and Novartis Pharmaceutical Corporation.

Education - Dr Shmeis holds a PhD in Pharmaceutics and a Bachelor of Science in Pharmacy.

She has a record of invited presentations at national and international conferences, publications in peer-reviewed journals as well as several patents.

Top shelf experience in the USA market

Commenting on the appointment, Radiopharm’s Chief Executive Officer & Managing Director, Riccardo Canevari, said: “We’re obviously thrilled to add another excellent senior team member with top shelf experience in the USA market.”

© 2023 Krish Capital Pty. Ltd., Data, and image source: Company update

At the time of writing this article (Wed, 11 Jan, 11:47 AM AEST), the share price of Radiopharm was noted at AU$0.130.